In vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 5, 2007, Pages 1849-1851

  Shen, Gwan Han ^a,b   Wu, Bo Da ^a   Wu, Kun Ming ^c   Chen, Jiann Hwa ^b  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c Rui Fu Shi Medical Laboratory   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; GENTAMICIN; ISEPAMICIN; KANAMYCIN; STREPTOMYCIN; TOBRAMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYOBACTERIA ABSCESSUS; MYOBACTERIUM CHELONAE; MYOBACTERIUM FORTUITUM; NONHUMAN; PRIORITY JOURNAL; TAIWAN;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CAPREOMYCIN SULFATE; GENTAMICINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIA, ATYPICAL; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM FORTUITUM;

EID: 34248355867     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01551-06     Document Type: Article

References (18)

1. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America. 1997. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am. J. Respir. Crit. Care Med. 156:S1-S25.
2. Barrett, M. S., R. N. Jones, M. E. Erwin, and F. P. Koontz. 1992. CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum. Diagn. Microbiol. Infect. Dis. 15:169-171.
3. Blum, D. 1995. An overview of the safety of isepamicin in adults. J. Chemother. 7(Suppl. 2):87-93.
4. Cheng, N. C., P. R. Hsueh, Y. C. Liu, J. M. Shyr, W. K. Huang, L. J. Teng, and C. Y. Liu. 2005. In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan. Microb. Drug Resist. 11:330-341.
5. Dalovisio, J. R., G. A. Pankey, R. J. Wallace, and D. B. Jones. 1981. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei. Rev. Infect. Dis. 3:1068-1074.
6. De Groote, M. A., and G. Huitt. 2006. Infections due to rapidly growing mycobacteria. Clin. Infect. Dis. 42:1756-1763.
7. Ho, Y. I., C. Y. Chan, and A. F. Cheng. 1997. In-vitro activities of aminoglycoside-aminocyclitols against mycobacteria. J. Antimicrob. Chemother. 40: 27-32.
8. Kondo, S., and K. Hotta. 1999. Semisynthetic aminoglycoside antibiotics: development and enzymatic modifications. J. Infect. Chemother. 5:1-9.
9. Lévy-Frébault, V., M. Daffé, K. S. Goh, M. A. Lanéelle, C. Asselineau, and H. L. David. 1983. Identification of Mycobacterium fortuitum and Mycobacterium chelonei. J. Clin. Microbiol. 17:744-752.
10. Metchock, B. G., F. S. Nolte, and R. J. Wallace. 1999. Mycobacterium, p. 399-437. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. ASM Press, Washington, DC.
11. National Committee for Clinical Laboratory Standards. 2002. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes. Tentative standards, second edition. M24-T2. National Committee for Clinical Laboratory Standards, Wayne, PA.
12. Petrini, B. 2006. Mycobacterium abscessus: an emerging rapid-growing potential pathogen. APMIS 114:319-328.
13. Telenti, A., F. Marchesi, M. Balz, F. Bally, E. C. Bottger, and T. Bodmer. 1993. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J. Clin. Microbiol. 31:175-178.
14. Tod, M., C. Padoin, and O. Petitjean. 2000. Clinical pharmacokinetics and pharmacodynamics of isepamicin. Clin. Pharmacokinet. 38:205-223.
15. Wallace, R. J., Jr., J. M. Swenson, V. A. Silcox, and M. G. Bullen. 1985. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J. Infect. Dis. 152:500-514.
16. Woods, G. L. 2000. Susceptibility testing for mycobacteria. Clin. Infect. Dis. 31:1209-1215.
17. Woods, G. L., J. S. Bergmann, F. G. Witebsky, G. A. Fahle, A. Wanger, B. Boulet, M. Plaunt, B. A. Brown, and R. J. Wallace, Jr. 1999. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J. Clin. Microbiol. 37:1676-1682.
18. Yang, S. C., P. R. Hsueh, H. C. Lai, L. J. Teng, L. M. Huang, J. M. Chen, S. K. Wang, D. C. Shie, S. W. Ho, and K. T. Luh. 2003. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob. Agents Chemother. 47:1958-1962.